Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).

Eduard SchmulensonCédric BovetRegula TheurillatLaurent Arthur DecosterdCarlo R LargiadèrJean-Christophe ProstChantal CsajkaDaniela BärtschiMatthias GuckenbergerRoger von MoosSara BastianMarkus JoergerUlrich Jaehde

Published in: British journal of clinical pharmacology (2022)

This work informs the clinical development of regorafenib and capecitabine combination treatment and underlines the importance of studying potential DDI with new anticancer drug combinations.

Keyphrases

locally advanced
rectal cancer
metastatic colorectal cancer
neoadjuvant chemotherapy
phase ii study
squamous cell carcinoma
radiation therapy
clinical trial
emergency department
randomized controlled trial
human health
climate change
electronic health record
drug induced
phase iii